Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 1

Status

Unknown 16Recruiting 7Not yet recruiting 7Terminated 2Completed 2Withdrawn 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Genitourinary 1

Conditions

Stomach Neoplasms 2Prostatic Neoplasms 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

pembrolizumab 563Specimen Handling 493Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 405Radiotherapy 353Bevacizumab 314Gemcitabine 313Paclitaxel 298Biopsy 292Drug Therapy 284Blood Specimen Collection 248Capecitabine 246Oxaliplatin 241fludarabine 239Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 206Dexamethasone 188Radiosurgery 182Standard of Care 159Rituximab 159Pemetrexed 156Surgical Procedures, Operative 148atezolizumab 146durvalumab 145Leucovorin 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × SHR-1701 × Clear all
NCT07451795 2026-04-30

SHARP

Fudan University

Phase 2 Recruiting
66 enrolled
Genitourinary

Prostatic Neoplasms

NCT07294664 2026-04-16

PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 2 Recruiting
78 enrolled
Gastrointestinal

Advanced Gastric Cancer

NCT05671822 2026-02-12

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2 Recruiting
258 enrolled
Gastrointestinal

HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

NCT07311408 2025-12-31

SHR-2554

China Medical University, China

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07175220 2025-11-18

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07102901 2025-09-10

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
351 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06893887 2025-07-02

ICT-HCC

Nanjing Tianyinshan Hospital

Phase NA Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡